Search Results - cell+therapy

13 Results

Sort By:

Human and Nonhuman Primate Hematopoietic Stem/Repopulating Cells and Methods for Enriching The Same

Selection and Use of Hematopoietic Stem Cells for Cell Transplantation and Gene Therapy Approaches Defined population predicts and quantitatively correlates with <em>in vivo</em> engraftment and multilineage potential. Hematopoietic stem cells (HSC) are the preferred target population for <em>ex vivo</em> gene therapy...

Published: 4/16/2025 | Updated: 8/28/2024 | Inventor(s): HanS-Peter Kiem, Jennifer Adair, Stefan Radtke

Keywords(s): HSC Therapy

Category(s): Cell Therapy, Gene Therapy

CCNA1 TCRs

CCNA1 TCRs for AML and solid tumors High-affinity HLA-A2 restricted TCRs for the treatment of AML and several solid tumors. Cancer-testis antigen cyclin A1 (CCNA1) is an alternative A-type cyclin and is thought to promote cell proliferation (specifically at the G1/S transition) and survival, has been shown to be leukemogenic in mice....

Published: 5/15/2025 | Updated: 12/12/2023 | Inventor(s): Rachel Perret, Philip Greenberg

Keywords(s): Immuno Oncology

Category(s): Cell Therapy

Markers for identification and sorting of neoantigen specific CD4 T cells from solid tumors

CD4+ T cell markers, compositions, and methods for cancer therapy Markers, methods, and compositions for identifying CD4+ T cells (or T cell receptor genes thereof) with tumor antigen specificity, tumor neoantigen specificity, and/or tumor-infiltrating capacity. While cancer immunotherapies have historically focused on CD8+ T cells, tumor antigen...

Published: 12/5/2023 | Updated: 12/5/2023 | Inventor(s): Joshua Veatch, Stanley Riddell

Keywords(s): Immuno Oncology

Category(s): Cell Therapy

MHC class II restricted T cell receptors targeting mutations in EGFR

MHC class II restricted T cell receptors targeting mutations in EGFR Compositions and methods for targeting EGFR antigens (for e.g., to treat or manage cancer) Activating mutations in EGFR cause a subset of non-small cell lung cancer that occurs preferentially in women and non-smokers. EGFR mutated lung cancer responds to small molecule kinase...

Published: 12/5/2023 | Updated: 12/5/2023 | Inventor(s): Joshua Veatch, Stanley Riddell

Keywords(s): Immuno Oncology

Category(s): Cell Therapy, Therapeutic

Engineering B cells as a tunable source of secreted proteins

Engineering B cells to secrete select antibodies and gene products for the treatment of diseases Method to produce B cells that can provide prolonged and tunable expression of select antibodies and gene products for the treatment of diseases (for e.g., lysosomal storage diseases) Several medical disorders are caused by an insufficiency of a...

Published: 7/12/2023 | Updated: 7/12/2023 | Inventor(s): Justin Taylor, Julia McKechnie, Carson Harms

Keywords(s): Nucleic Acid, Protein / Peptide

Category(s): Cell Therapy

Mesothelin directed chimeric antigen receptor T cells for treatment of acute myeloid leukemia

Mesothelin-directed CAR T Cells for the Treatment of Acute Myeloid Leukemia CAR T cells targeting mesothelin to treat Leukemia Despite maximally intensive therapy, approximately 40% of patients with acute myeloid leukemia (AML) will relapse. An effective targeted therapy is still needed to save the lives of AML patients. Through computational...

Published: 10/14/2024 | Updated: 1/20/2023 | Inventor(s): Soheil Meshinchi, Quy Le, Rhonda Ries

Keywords(s): Biomarker, Target, Vectors

Category(s): Cell Therapy

High Affinity MAGE-A1 T-cell Receptors

TCR Cell Therapy Targeting MAGE-A1 High-affinity MAGE-A1-specific TCR for the treatment of multiple myeloma and solid tumors. The MAGE family are CTAs expressed in many tumor types and MAGE-A1 has been shown to directly drive tumorigenesis. Specifically, MAGE-A1 is expressed in about 50% of multiple myeloma, up to 60% in triple negative...

Published: 5/15/2025 | Updated: 1/19/2023 | Inventor(s): Aude Chapuis, Thomas Schmitt, Megan McAfee

Keywords(s): Immuno Oncology, Target

Category(s): Cell Therapy, Therapeutic

Chimeric antigen receptor designs for improved recognition of low-density antigens

CAR Design Improvements for the Recognition of Low-Density Antigens Methods and tools to increase CAR-T cell recognition of tumor cells expressing low density antigens Adoptive transfer of CAR-expressing T cells is an effective cancer therapy for a proportion of individuals with B cell malignancies and multiple myeloma, but efficacy is limited...

Published: 8/28/2024 | Updated: 5/21/2020 | Inventor(s): Alexander Salter, Stanley Riddell, Anusha Rajan

Keywords(s): Immuno Oncology

Category(s): Cell Therapy

Methods to Expand and Manipulate Hematopoietic Stem and Progenitor Cells

Methods to expand and manipulate hematopoietic stem and progenitor cells Culture strategies for cost effective, ex vivo expansion of hematopoietic stem and progenitor cells (HSPCs) with enhanced in vivo repopulating ability. HSPCs can be used to treat over 70 types of diseases including a variety of hematological disorders through transplantation...

Published: 10/14/2024 | Updated: 12/19/2019 | Inventor(s): Irwin Bernstein, Chengcheng Zhang, Mi Deng, Zhigang Lu, Junke Zheng

Keywords(s): HSC Therapy

Category(s): Cell Therapy

MAIT CTLA4

MAIT Cell Immunomodulation for Targeted Treatment of Inflammatory Diseases MAIT cells undergo targeted therapeutic exploitation to alter CTLA-4 expression and dampen inflammatory responses. Mucosal-associated invariant T (MAIT) cells are non-conventional T cells that localize within inflamed tissue. Upon activation, MAIT cells act as...

Published: 12/27/2023 | Updated: 10/22/2019 | Inventor(s): Martin Prlic, Julia Berkson, Chloe Slichter

Keywords(s): Assay / Method

Category(s): Cell Therapy

1 2